Literature DB >> 10680793

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.

R Van Koningsveld1, P A Van Doorn, P I Schmitz, C W Ang, F G Van der Meché.   

Abstract

OBJECTIVE: Assessment of incidence rates of Guillain-Barré syndrome (GBS) in the Netherlands over a 10-year period; investigation of a relationship between possible seasonality in GBS and the occurrence of preceding infections; and determination of distinctive characteristics in patients with GBS who are only mildly affected (able to walk unaided at nadir).
METHOD: Records of patients with GBS admitted between 1987 and 1996 from all 45 hospitals in the southwest Netherlands were evaluated, covering a population of 4.2 million inhabitants.
RESULTS: A total of 476 patients met National Institute for Neurological and Communicative Disorders and Stroke criteria for GBS. This resulted in a crude incidence rate (IR) of 1.18/100,000 inhabitants. This IR increased linearly with age (p < 0.001). Men were more frequently affected than women (p < 0.001). No seasonal preponderance for GBS, nor for any of the preceding infections, was found. Patients under 50 years of age (p < 0.001) and men (p = 0.01) were more frequently found in the mildly affected group. In both groups a preceding infection was reported in 70% of the cases. In the severely affected group, serologic evidence for infection with Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, or Mycoplasma pneumoniae was found more frequently than in the mildly affected group (41% versus 16%, p = 0.001).
CONCLUSIONS: Overall IR in the Netherlands are similar to those found in other studies. The incidence increases linearly with age and men are more frequently affected than women. Distinctive characteristics for mildly and severely affected patients were found regarding age, sex, and preceding infections. This suggests that other infectious agents or host factors may be involved in mild forms of GBS.

Entities:  

Mesh:

Year:  2000        PMID: 10680793     DOI: 10.1212/wnl.54.3.620

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

Authors:  James J Sejvar; Andrew L Baughman; Matthew Wise; Oliver W Morgan
Journal:  Neuroepidemiology       Date:  2011-03-21       Impact factor: 3.282

Review 3.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

4.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

5.  Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years.

Authors:  Sibel Karaca; İlknur Kozanoğlu; Başak Karakurum Göksel; Mehmet Karataş; Meliha Tan; V Deniz Yerdelen; Semih Giray; Zülfikar Arlier
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

Review 6.  Epidemiology of neuroimmunological diseases.

Authors:  Peter Flachenecker
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

7.  Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome.

Authors:  M P J Garssen; R Van Koningsveld; P A Van Doorn
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 8.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 9.  Advances in the management of Guillain-Barré syndrome.

Authors:  Deborah M Green
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

10.  Epidemiology of Guillain-Barré Syndrome in Aruba.

Authors:  Franciska S T Suryapranata; C Wim Ang; Luis L Chong; Jean-Luc Murk; Jaime Falconi; Ralph M H G Huits
Journal:  Am J Trop Med Hyg       Date:  2016-03-28       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.